Cargando…
845. Clinical Outcomes in Patients Treated with High vs. Standard Dose Liposomal Amphotericin B for Invasive Mucormycosis
BACKGROUND: Mucormycosis is a life-threatening invasive fungal infection associated with high mortality. Amphotericin B is first-line therapy; however, the benefit of high doses remains uncertain. The purpose of this study is to describe outcomes in patients treated with high dose versus standard do...
Autores principales: | Valiante, Sarah, Elshaboury, Ramy H, Wu, Tiffany, Reyes, Fabiola, Lahoud, Chloe, Franceschi, Andres E, Koo, Sophia, Letourneau, Alyssa R, Hammond, Sarah P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677825/ http://dx.doi.org/10.1093/ofid/ofad500.890 |
Ejemplares similares
-
Successful treatment of cutaneous mucormycosis disseminated from pulmonary mucormycosis with liposomal amphotericin B and posaconazole
por: Ding, Xiao-Lan, et al.
Publicado: (2020) -
Bronchoscopic instillation of liposomal amphotericin B in management of nonresponding endobronchial mucormycosis
por: Nattusamy, Loganathan, et al.
Publicado: (2017) -
1554. Nebulized Liposomal Amphotericin B for Treatment of Murine Pulmonary Mucormycosis
por: Sandoval, Adilene, et al.
Publicado: (2019) -
Sinonasal mucormycosis and liposomal amphotericin B: A quest for dose optimization
por: Kajal, Smile, et al.
Publicado: (2022) -
Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2021)